Advisory
Stanford Medicine
A Stanford Medicine-led clinical trial has shown that about one-third of children with severe food allergies can safely consume full servings of allergenic foods after treatment. The study, published in JAMA Pediatrics, tested omalizumab, an FDA-approved drug for accidental exposure protection, in combination with oral immunotherapy.
These findings expand treatment options for food allergy sufferers, offering both safety and lifestyle improvements. The trial reinforces Stanford Medicine’s leadership in allergy research, with potential implications for healthcare delivery and pharmaceutical collaborations.
Investment implication: This breakthrough strengthens Stanford Medicine’s research profile, likely attracting new funding and partnerships. For you, it highlights the financial and reputational impact of academic medical centers driving innovation in healthcare.